The current classification of acute myeloid leukemia (AML) relies largely on genomic alterations. AML with mutated nucleophosmin 1 (NPM1-mut) is the largest genetically defined groups, involving about 30% adult AMLs and currently recognized as a distinct entity in actual classifications. NPM1-mut usually occurs de novo associated predominantly normal karyotype relatively favorable prognosis. Ho...

OBJECTIVE Intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML cases, is highly heterogeneous. We systematically summarize the latest research progress on the significance of gene mutations for prognostic stratification of IR-AML. DATA SOURCES We conducted a systemic search from the PubMed database up to October, 2014 using various search terms and...

Background: Acute myeloid leukemia (AML) is a dangerous type of leukemia. The emergence multidrug resistance (MDR) and recurrence limits the prognosis survival patients. In recent studies, we have known that bone marrow microenvironment was closely related to poor AML. However, underlying mechanisms are still far from fully understood. By utilizing bioinformatics analysis, screened out integrin...

Acute myeloid leukemia (AML) in children is a complex and heterogeneous disease. The identification of reliable and stable molecular biomarkers for diagnosis, especially early diagnosis, remains a significant therapeutic challenge. Aberrant microRNA expression could be used for cancer diagnosis and treatment selection. Here, we describe a novel bioinformatics model for the prediction of microRN...

A 62-year-old female was diagnosed with acute myeloid leukemia (AML) t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days the CBT, a bone marrow examination revealed relapse. We treated patient venetoclax plus azacitidine as salvage therapy. After five cycles of therapy, died due ...

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disorder encompassing set of hematopoietic tumors that develop when the precursor cells undergo disproportionate clonal proliferation. Homeobox A 9 ( HOXA9 ) pioneer transcription factor in AML pathogenesis along with its cofactor ecotropic integration site 1 MEIS1 ). Our work aimed to evaluate different expression levels and g...

OBJECTIVE Signaling pathways such as extracellular regulated kinase/mitogen activated protein kinase (ERK/MAPK) have increased activity in leukemia. Ribosomal 6 kinase (RSK4) is a factor downstream of the MAPK/ERK pathway and an important tumor suppressor which inhibits ERK trafficking. Decrease in RSK4 expression has been reported in some malignancies, which leads to an increase in growth and ...

Acute myeloid leukemia (AML) is associated with poor prognosis in elderly patients. More effective, less toxic therapies for older patients with AML who are not eligible for standard intensive induction therapy or have refractory or relapsed disease after chemotherapy are urgently needed. Epigenetic approaches with hypomethylating agents and histone deacety‐ lase inhibitors and immunomodulatory...

Acute myeloid leukemia (AML) is the most common and incurable subtype. Despite extensive research into disease’s intricate molecular mechanisms, effective treatments or expanded diagnostic prognostic markers for AML have not yet been identified. The morphological, immunophenotypic, cytogenetic, biomolecular, clinical characteristics of patients are complex. Leukemia stem cells (LSCs) consist he...

Abstract NK cells mediate anti-leukemic immunosurveillance in AML. We hypothesized that impaired predict poor outcomes analyzed the expression of receptors on CD56 cell subsets and their corresponding ligands CD45dim blast by flow cytometry 100 AML 17 healthy bone marrows. Risk stratification, complete remission, relapse, measurable residual disease, overall survival, relapse-free ligand expres...